Your data on MRCVSonline
The nature of the services provided by Vision Media means that we might obtain certain information about you.
Please read our Data Protection and Privacy Policy for details.

In addition, (with your consent) some parts of our website may store a 'cookie' in your browser for the purposes of
functionality or performance monitoring.
Click here to manage your settings.
If you would like to forward this story on to a friend, simply fill in the form below and click send.

Your friend's email:
Your email:
Your name:
 
 
Send Cancel

New therapy offers hope for headshakers
horse
Headshaking affects 10,000 to 20,000 horses in the UK and can result in euthanasia.

Bristol researchers believe PENS therapy could reduce clinical signs

A new therapy based on electrical nerve stimulation may be able to reduce the signs of headshaking in horses, Bristol researchers say.

Headshaking is caused by a neuropathic facial pain syndrome that can leave horses dangerous to handle and impossible to ride. It affects 10,000 to 20,000 horses in the UK.

Currently, there is no consistently safe and effective treatment and the condition can result in euthanasia.

A new study led by researchers from the University of Bristol suggests the symptoms may be reduced by percutaneous electrical nerve stimulation (PENS) - the same therapy used for humans with neuropathic pain.

Facial pain syndromes in people - particularly trigeminal neuralgia - bear striking clinical resemblance to headshaking in horses. A team from the University of Bristol worked alongside neurologists at Southmead Hospital Bristol to determine whether PENS therapy could offer a safe, effective and sustainable solution for horses.

Seven horses with trigeminal mediated headshaking were selected for the study. All horses were sedated during the procedure and an area the size of a needle-prick was desensitised with local anaesthetic.

A disposable PENS probe was inserted just underneath the skin adjacent to the nerve under ultrasonic guidance. The nerve was stimulated for 25 minutes and the probe was then removed and the procedure repeated on the other side. Three to four treatments were used and the therapy was repeated when signs recurred.

According to findings published in the Equine Veterinary Journal, all horses tolerated the procedure well. Of the seven horses involved in the trial, two developed a haematoma at the site on one occasion; two showed increased clinical signs for up to three days after the first treatment; six responded well after the first treatment and returned to the same level of ridden work as before the onset of symptoms; and five continued to respond to further treatment.

Commenting on the study, Veronica Roberts, senior clinical fellow in Equine Medicine at the University of Bristol, said: "Headshaking in horses is a major welfare issue and can be a significant cause of distress.
 


"Although it is clear that further work is required, including increasing the number of cases and refining the treatment procedures, the study shows that PENS therapy should be the first-line treatment for trigeminal-mediated headshakers, which have failed to respond to conservative treatment, such as nose-nets."

The paper can be found online at: http://onlinelibrary.wiley.com/doi/10.1111/evj.12394/abstract

Become a member or log in to add this story to your CPD history

FIVP launches CMA remedies survey

News Story 1
 FIVP has shared a survey, inviting those working in independent practice to share their views on the CMA's proposed remedies.

The Impact Assessment will help inform the group's response to the CMA, as it prepares to submit further evidence to the Inquiry Group. FIVP will also be attending a hearing in November.

Data will be anonymised and used solely for FIVP's response to the CMA. The survey will close on Friday, 31 October 2025. 

Click here for more...
News Shorts
CMA to host webinar exploring provisional decisions

The Competition and Markets Authority (CMA) is to host a webinar for veterinary professionals to explain the details of its provisional decisions, released on 15 October 2025.

The webinar will take place on Wednesday, 29 October 2025 from 1.00pm to 2.00pm.

Officials will discuss the changes which those in practice may need to make if the provisional remedies go ahead. They will also share what happens next with the investigation.

The CMA will be answering questions from the main parties of the investigation, as well as other questions submitted ahead of the webinar.

Attendees can register here before Wednesday, 29 October at 11am. Questions must be submitted before 10am on 27 October.

A recording of the webinar will be accessible after the event.